Zevra revenue jumps 45% on U.S. sales of MIPLYFFA
Zevra reported third-quarter revenue of $37.8M, up 45% year on year, with $270.9M in cash and investments. Source: TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Zevra reported third-quarter revenue of $37.8M, up 45% from a year earlier. Most of it came from $34M in U.S. sales of MIPLYFFA. The company held $270.9M in cash and investments at the end of the period.
Among its priorities, Zevra named an infant-label sNDA filing planned for Q1 2027, broader global access to the drug, and development of celiprolol. The information is attributed to TradingView.
why it matters
Two points matter for investors: the revenue growth rests on a single product, and a large cash balance gives the company room to fund new programs. For a small biotech issuer, quarterly figures like these often drive interest in the shares.
market impact
ZVRA shares: revenue growth and a large cash position support interest in the stock
- ZVRA pressure up — revenue rose 45% on U.S. sales of MIPLYFFA
tags
instruments
sources
- ZVRA: MIPLYFFA-led revenue grew 45%, supporting expansion and pipeline investment — TradingView, 3 November 2026 at 22:58 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗